Condition: HIV · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This is a phase 1, multicenter, open-label, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of DV201P-RNA and DV202B1-RNA, immunogens designed to induce HIV-1 envelope (Env) V2 apex-specific broadly neutralizing antibodies (V2 apex bnAbs). Both vaccines consist of a modified mRNA encapsulated in lipid nanoparticles (LNP) that when translated in cells produces HIV-1 Env gp150 transmembrane trimers. The trial will enroll adult volunteers without HIV and in overall good health.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| The Ponce de Leon Center CRS | Atlanta, Georgia, United States | Not Yet Recruiting |
| The Hope Clinic of the Emory Vaccine Research Center; Emory University | Decatur, Georgia, United States | Recruiting |
| Beth Israel Deaconess Medical Center VCRS (BIDMC VCRS Site # 32077) | Boston, Massachusetts, United States | Recruiting |
| Columbia P&S CRS (Site ID: 30329) | New York, New York, United States | Recruiting |
| University of Rochester Vaccines to Prevent HIV Infection CRS (Site ID 31467) | Rochester, New York, United States | Recruiting |
| Penn Prevention CRS | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
| University of Pittsburgh CRS | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07390474